Congenital adrenal hyperplasia (AGS)
Conditions
Interventions
After the informed consent procedure, each patient will recieve the same total daily medication dosage from their own initial pre-study treatment, starting with either the biggest dosage of hydrocorti
Sponsors
Radboudumc, Department of pediatric endocrinology
Eligibility
Inclusion criteria
Inclusion criteria: • Children and adolescents with CAH due to 21-hydroxylase deficiency > 4 years old • The diagnosis is confirmed by mutation analysis • Patient are treated with hydrocortisone according to standard guidelines in a thrice daily schedule • Ability to collect saliva
Exclusion criteria
Exclusion criteria: • Other forms of CAH • Not able to collect saliva • Chronical medication use other than hydrocortisone and fludrocortisone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentrations of salivary 17OHP and A after 3 weeks of treatment with the 2 different timing strategies. | — |
Secondary
| Measure | Time frame |
|---|---|
| 12 Hours blood pressure and activity and sleeping patters during the 2 treatment strategies. | — |
Contacts
Public ContactHedi Claahsen - van der Grinten, MD PhD
Radboudumc
Outcome results
None listed